Gunzburg spoke about the development of platforms for rapid adaptation of vaccines

TASS informs about it.

According to him, the situation with the emergence of new variants of the coronavirus shows that an important area is the ability to quickly adjust vaccines for these strains.

Gunzburg said two alternative platforms have been developed to meet this challenge, allowing for rapid vaccine changes.

“We are now moving on to the preclinic (preclinical studies. -

),

both on one and the second platform

, which, I hope, will start in summer, if not in May,” he said.

Gunzburg also said that registration of a nasal vaccine against coronavirus infection could occur in 2022.